Alfonso Prieto, MD
Clinical Cardiac Electrophysiology · Albany, NYNPI 1063411783
Payments from drug & device makers
Across 283 payments — averaging $30.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Abbott$897
- Boehringer Ingelheim$849
- Boston Scientific$742
- Novartis$700
- E.r. Squibb & Sons, L.L.C.$325
- plus $2K from 26 others
What the payments were for
- Travel & lodging$1,88022%
- Food & beverage$6,69678%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 40 | $2,806 |
| Abbott | 9 | $897 |
| Boehringer Ingelheim | 46 | $849 |
| Boston Scientific | 16 | $742 |
| Novartis | 58 | $700 |
| E.r. Squibb & Sons, L.L.C. | 18 | $325 |
| Pfizer | 12 | $272 |
| Biosense Webster, Inc. | 4 | $265 |
| Amgen | 13 | $250 |
| Abiomed | 7 | $206 |
| Johnson & Johnson | 9 | $191 |
| Edwards Lifesciences | 7 | $168 |
| Baxter Healthcare | 3 | $164 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $127 |
| Regeneron Healthcare Solutions, Inc. | 5 | $87 |
| Merck | 5 | $83 |
| AstraZeneca | 5 | $77 |
| Scpharmaceuticals Inc. | 4 | $74 |
| Lexicon Pharmaceuticals, Inc. | 3 | $51 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $37 |
| Philips North America LLC | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Kestra Medical Technology Services, Inc. | 1 | $25 |
| Lantheus Medical Imaging, Inc. | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Cardiva Medical, Inc. | 1 | $22 |
| Bayer | 1 | $21 |
| Ionis Pharmaceuticals, Inc. | 1 | $20 |
| Novo Nordisk | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Irhythm Technologies, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Performa$1,276
- AMPLATZER$587
- Micra$441
- Carto 3$217
- Advisa$154
- WATCHMAN Access System$140
- Confirm Rx$130
- WATCHMAN FLX$128
- Watchman$121
- JARDIANCE$114
- Capsure$104
How this compares
$8,637 in reported general payments places this provider in the 25th percentile of 214 clinical cardiac electrophysiology providers in New York.
See all clinical cardiac electrophysiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,594 | $2,132,759 |
| XareltoRivaroxaban | 224 | $302,920 |
| EntrestoSacubitril/Valsartan | 152 | $204,013 |
| Repatha SureclickEvolocumab | 54 | $76,859 |
| MultaqDronedarone Hcl | 33 | $53,664 |
| JardianceEmpagliflozin | 31 | $35,542 |
| Propafenone Hcl ErPropafenone Hcl | 57 | $20,834 |
| Metoprolol Succinate | 930 | $18,472 |
| Dofetilide | 31 | $14,557 |
| FarxigaDapagliflozin Propanediol | 12 | $14,123 |
| Amiodarone Hcl | 358 | $14,113 |
| Flecainide Acetate | 289 | $12,200 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 34 | $12,055 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 330 | $11,040 |
| PradaxaDabigatran Etexilate Mesylate | 24 | $9,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $272 | $2,132,7591,594 claims |
| Johnson & JohnsonXarelto | $191 | $302,920224 claims |
| NovartisEntresto | $700 | $204,013152 claims |
| Boehringer IngelheimJardiance, Pradaxa | $849 | $44,97855 claims |
| AstraZenecaFarxiga | $77 | $14,12312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 214 clinical cardiac electrophysiology providers in New York.
Other clinical cardiac electrophysiology in Albany
- Robert PhangAlbany$545K
- Vivek ReddyNew York$16.7M
- Srinivas DukkipatiNew York$4.2M
- Jacob KoruthNew York$4M
- Stavros MountantonakisManhasset$2.6M
- Jorge RomeroSyracuse$2.6M
- Larry ChinitzNew York$2.6M
- David HuangRochester$2.2M
- James IpNew York$1.2M
- Jonathan WillnerStaten Island$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.